These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Exploring multitarget potential of Piper nigrum fruit constituents for Alzheimer's disease: An AI-driven strategy. Bhanukiran K; Priya V Phytomedicine; 2024 Dec; 135():156108. PubMed ID: 39383634 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and molecular docking study of xanthene-linked thiosemicarbazones as cholinesterase inhibitors. Naseem S; Khan S; Hussain S; Mirza MU; Ashraf M; Shafiq Z; Trant JF J Biomol Struct Dyn; 2024; 42(23):13232-13246. PubMed ID: 37948312 [TBL] [Abstract][Full Text] [Related]
7. Efficient Access to New Thienobenzo-1,2,3-Triazolium Salts as Preferred Dual Cholinesterase Inhibitors. Mlakić M; Sviben M; Ratković A; Raspudić A; Barić D; Šagud I; Lasić Z; Odak I; Škorić I Biomolecules; 2024 Oct; 14(11):. PubMed ID: 39595567 [TBL] [Abstract][Full Text] [Related]
8. Sertraline as a Multi-Target Modulator of AChE, COX-2, BACE-1, and GSK-3β: Computational and In Vivo Studies. Arfeen M; Mani V Molecules; 2024 Nov; 29(22):. PubMed ID: 39598743 [TBL] [Abstract][Full Text] [Related]
9. Discovery of new 4-aminoquinoline derivatives containing an amine or hydroxamic acid terminal as multifunctional agents for the treatment of Alzheimer's disease. Zhai B; Hao Q; Wang M; Luo Z; Yang R; Yang J; Cao Y Bioorg Chem; 2024 Dec; 153():107954. PubMed ID: 39571302 [TBL] [Abstract][Full Text] [Related]
10. Naphthyl-functionalized acetamide derivatives: Promising agents for cholinesterase inhibition and antioxidant therapy in Alzheimer's disease. Camargo-Ayala L; Prent-Peñaloza L; Osorio E; Camargo-Ayala PA; Jimenez CA; Zúñiga-Arbalti F; Brito I; Delgado GE; Gutiérrez M; Polo-Cuadrado E Bioorg Chem; 2024 Dec; 153():107896. PubMed ID: 39454497 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, molecular docking and molecular dynamics simulations of novel 2,5-disubstituted-1,3,4-thiadiazole derivatives as potential cholinesterase/monoamine oxidase dual inhibitors for Alzheimer's disease. Al-Sharabi AA; Evren AE; Sağlık BN; Yurttaş L J Biomol Struct Dyn; 2024; 42(23):13023-13041. PubMed ID: 37909464 [TBL] [Abstract][Full Text] [Related]
12. Emodin derivatives as promising multi-aspect intervention agents for amyloid aggregation: molecular docking/dynamics simulation, bioactivities evaluation, and cytoprotection. Shen R; Zhao W; Li X; Liu J; Yang A; Kou X Mol Divers; 2024 Oct; 28(5):3085-3099. PubMed ID: 37737959 [TBL] [Abstract][Full Text] [Related]
13. Exploring the diverse acetylcholinesterase inhibitory potential of girinimbine: insights from in vitro assays, molecular docking, and simulation studies. Taha MME; Khalid A; Elfatih F; Mohan S; Sukumaran SD; Ul-Haq Z; Aljahdali IA; Oraibi O; Oraibi B; Alfaifi HA; Alzahrani AH; Farasani A; Jerah AA; Babiker YOH; Abdelwahab SI Cell Mol Biol (Noisy-le-grand); 2024 Nov; 70(10):154-160. PubMed ID: 39605111 [TBL] [Abstract][Full Text] [Related]
14. Anticholinesterase and Anti-Inflammatory Activities of the Essential Oils of Sawdust and Resin-Rich Bark from Azorean Lima A; Arruda F; Frias J; Wortham T; Janeiro A; Rodrigues T; Baptista J; Lima E Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596392 [TBL] [Abstract][Full Text] [Related]
15. A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease. Chhabra A; Solanki S; Saravanabawan P; Venkiteswaran A; Nimmathota N; Modi NM Expert Opin Biol Ther; 2024 Nov; 24(11):1261-1269. PubMed ID: 39432414 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel thiosemicarbazone-acridine targeting butyrylcholinesterase with antioxidant, metal complexing and neuroprotector abilities as potential treatment of Alzheimer's disease: In vitro, in vivo, and in silico studies. Silva Sousa GL; Nadur NF; de Almeida Peixoto Ferreira L; da Silva Honório T; Simon A; Cabral LM; Móra Santos ML; Andrade B; de Lima EV; Clarke JR; Castro RN; Olímpio de Moura R; Kümmerle AE Eur J Med Chem; 2025 Jan; 281():117030. PubMed ID: 39531933 [TBL] [Abstract][Full Text] [Related]
17. Identification of AChE targeted therapeutic compounds for Alzheimer's disease: an in-silico study with DFT integration. Rawat K; Tewari D; Bisht A; Chandra S; Tiruneh YK; Hassan HM; Al-Emam A; Sindi ER; Al-Dies AM Sci Rep; 2024 Dec; 14(1):30356. PubMed ID: 39638823 [TBL] [Abstract][Full Text] [Related]
18. Rivastigmine structure-based hybrids as potential multi-target anti-Alzheimer's drug candidates. Leuci R; Simic S; Carrieri A; Chaves S; La Spada G; Brunetti L; Tortorella P; Loiodice F; Laghezza A; Catto M; Santos MA; Tufarelli V; Wackerlig J; Piemontese L Bioorg Chem; 2024 Dec; 153():107895. PubMed ID: 39454499 [TBL] [Abstract][Full Text] [Related]
19. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Lim AWY; Schneider L; Loy C Cochrane Database Syst Rev; 2024 Nov; 11(11):CD001747. PubMed ID: 39498781 [TBL] [Abstract][Full Text] [Related]
20. Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease. Kim HY; Kim Y Acc Chem Res; 2024 Nov; 57(22):3266-3276. PubMed ID: 39496112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]